PHIA

Koninklijke Philips N.V. presents one of the most unusual structural narratives in European healthcare. A 135-year-old conglomerate that spent the better part of a decade transforming itself into a focused health technology company, Philips then suffered the single most damaging product quality event in modern medtech history: the Respironics sleep and respiratory care device recall announced in June 2021. The recall affected millions of CPAP and BiPAP devices globally, triggering regulatory consent decrees, class-action litigation, an FDA enforcement action, and a reputational wound that erased more than EUR 30 billion in market capitalization between its peak and trough. The company lost EUR 1.6 billion in 2022, EUR 466 million in 2023, and EUR 702 million in 2024. Three consecutive years of net losses from a company that had positioned itself as the innovation leader in connected care.

That sequence is what makes the current moment analytically significant. Full-year 2025 delivered EUR 896 million in net income, an EBIT margin of 9.2%, and free cash flow of EUR 903 million. Q1 2026 produced EUR 5.04 billion in revenue with a 25% EPS surprise. CEO Roy Jakobs, who took the helm in October 2022 specifically to manage the crisis, has executed a restructuring that reduced headcount to approximately 67,200, trimmed the cost base, and refocused innovation spending. Yet the market remains skeptical: at EUR 24.12 per share and a market capitalization of approximately EUR 23 billion, Philips trades at a price-to-earnings multiple of roughly 24.6x on 2025 earnings, well below the DCF-implied intrinsic value of approximately EUR 47 per share. The discount to fair value is not a function of misunderstanding. It is a function of unresolved trust.

The central analytical question is not whether Philips can generate earnings. It clearly can. The question is whether the structural damage from the Respironics crisis has permanently impaired Philips' ability to define its competitive space, or whether the company can reclaim its position as a top-tier medtech platform. The answer to that question determines whether the current valuation represents a structural mispricing or an accurate reflection of diminished competitive power. This is a company that did not lose its technology. It lost its permission to lead.